- TREATMENT OF DISEASES BY EPIGENETIC REGULATION
-
The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of cancer, including NUT midline carcinoma, Burkitt's Lymphoma, Acute Myelogenous Leukemia, and Multiple Myeloma; autoimmune or inflammatory diseases or conditions, and sepsis.
- -
-
Paragraph 0538
(2013/11/05)
-
- COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES
-
The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.
- -
-
Page/Page column 40
(2008/12/07)
-
- Synthesis of porphyrins designed for attachment to electroactive surfaces via one or more carbon tethers
-
Porphyrin compounds having a surface attachment group coupled thereto at the 5 position are described. The surface attachment group has the formula: wherein R is —CHCH2 or —CCH and Ar is an aromatic group. Methods and intermediates useful for m
- -
-
Page/Page column 7; 16
(2010/02/15)
-
- Synthesis of porphyrins bearing hydrocarbon tethers and facile covalent attachment to Si(100)
-
The use of redox-active molecules as the active storage elements in memory chips requires the ability to attach the molecules to an electroactive surface in a reliable and robust manner. To explore the use of porphyrins tethered to silicon via carbosilane
- Liu, Zhiming,Yasseri, Amir A.,Loewe, Robert S.,Lysenko, Audrey B.,Malinovskii, Vladimir L.,Zhao, Qian,Surthi, Shyam,Li, Qiliang,Misra, Veena,Lindsey, Jonathan S.,Bocian, David F.
-
p. 5568 - 5577
(2007/10/03)
-